RBC Capital Maintains Outperform on 4D Molecular Therapeutics, Raises Price Target to $35
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Luca Issi maintains an Outperform rating on 4D Molecular Therapeutics (NASDAQ:FDMT) and raises the price target from $25 to $35.
February 05, 2024 | 2:58 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
RBC Capital has maintained its Outperform rating on 4D Molecular Therapeutics and increased the price target from $25 to $35.
The upgrade in the price target by a reputable analyst like Luca Issi from RBC Capital is a strong positive signal for the stock. It suggests a higher level of confidence in the company's future performance and growth prospects, which can lead to increased investor interest and potentially a rise in the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100